Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Table 2 Survival analysis at final follow-up

Variable	Erlotinib (n = 112)	Gefitinib (n = 115)	p - value
median PFS (months)	10.8(range, 0–21.3)	8.4(range, 0–20.5)	0.014^*a
median OS (months)	28.3(range, 3.6–36.2)	25.0(range, 3.3–36.3)	0.033^*a
Deaths, No.	50	67	0.04^*b
Age(y)	68.1 ± 8.73	67.7 ± 9.34	0.175^c
Sex			0.133^b
Female	30	49
Male	20	18
Smoking status			0.770^d
Never a smoker	30	44
Former smokers	13	10
Current smokers	7	13
Largest size of brain metastasis			0.326^d
≤ 10 mm	11	10
> 10 mm	39	57
Number of brain metastasis			0.467^d
≤ 3	22	25
> 3	28	42
ECOG performance status			0.177^d
0	6	8
1	15	30
2	21	22
3	8	7

*Statistically significant. ^aAnalysed using the log-rank test; ^bAnalysed using independent-samples t-test; ^cAnalysed using chi-squared test; ^dAnalysed using the Mann-Whitney test. PFS progression-free disease-free survival; OS overall survival; ECOG Eastern Cooperative Oncology Group

ISSN: 1471-2466